Janus Henderson Group PLC Werewolf Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $182 Billion
- Q2 2024
A detailed history of Janus Henderson Group PLC transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 167,987 shares of HOWL stock, worth $369,571. This represents 0.0% of its overall portfolio holdings.
Number of Shares
167,987
Previous 1,688,054
90.05%
Holding current value
$369,571
Previous $10.9 Million
96.26%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding HOWL
# of Institutions
77Shares Held
32.1MCall Options Held
53.8KPut Options Held
1.3K-
Ra Capital Management, L.P. Boston, MA6.14MShares$13.5 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.28MShares$9.43 Million5.74% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.24MShares$7.13 Million0.41% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$5.25 Million0.94% of portfolio
-
Bank Of America Corp Charlotte, NC2.15MShares$4.72 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $65M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...